<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT931-1761</title>
	</head>
	<body>
		<main>
			<p>930324 FT  24 MAR 93 / People: Irwin joins British Bio British Bio-technology Group, one of the country's 'emerging' pharmaceutical com-panies, has brought in Ron Irwin, a veteran of the drugs industry, to plan the commercialisation of its products. As commercial director, Irwin will be responsible for marketing British Bio-technology's four candidate drugs now in clinical trials. He joined the pharmaceutical industry in 1960 and since 1989 has been chairman of the UK subsidiary of Marion Merrell Dow, the US drug company. The group has also appointed two non-executive directors: John Raisman, 64, who retired as chairman and chief executive of Shell UK in 1985 and was a non-executive director of Glaxo Holdings for eight years, and John Wilkerson, 50, chairman of The Wilkerson Group, a US health care consultancy, who has also worked with Smith Barney, Harris Upham and White Weld. Brian Dovey and David Jack are retiring.</p>
		</main>
</body></html>
            